Skip to main content
profile image
Selected Works of Philip Mease, MD
Presentation
Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis: 3-Year Efficacy and Safety Results From Phase 3 FUTURE 1 Trial. Maui Derm NP+PA Fall 2017 Meeting New Orleans, LA, Sep 2017.
Maui Derm NP+PA Fall 2017 Meeting (2017)
  • Philip Mease, Providence St. Joseph Health
  • et.al.
Link
Disciplines
Publication Date
September, 2017
Citation Information
Philip Mease and et.al.. "Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis: 3-Year Efficacy and Safety Results From Phase 3 FUTURE 1 Trial. Maui Derm NP+PA Fall 2017 Meeting New Orleans, LA, Sep 2017." Maui Derm NP+PA Fall 2017 Meeting (2017)
Available at: http://works.bepress.com/philip-mease/204/